Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DICE: Denosumab and Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer
NCT03869762Phase 2Terminated
- Sponsor
- Cancer Trials Ireland
- Start
- Jan 2019
- Primary completion
- Jan 2019
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of denosumab, enzalutamide in castration-resistant prostate cancer (CRPC), bone metastasis, sponsored by Cancer Trials Ireland. Started Jan 2019; status: terminated.
02
Drugs
denosumabenzalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)bone metastasis
Beyond the preview
Go deeper on NCT03869762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03869762.